Therapeutic Plasma Exchange to Reverse Plasma Failure in Multiple Organ Dysfunction Syndrome.
extracorporeal therapy
multi‐organ failure
sepsis
thrombotic microangiopathy
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
10
07
2024
received:
29
02
2024
accepted:
26
09
2024
medline:
18
10
2024
pubmed:
18
10
2024
entrez:
18
10
2024
Statut:
ppublish
Résumé
Plasma plays a crucial role in maintaining health through regulating coagulation and inflammation. Both are essential to respond to homeostatic threats such as traumatic injury or microbial infection; however, left unchecked, they can themselves cause damage. A well-functioning plasma regulatory milieu controls the location, intensity, and duration of the response to injury or infection. In contrast, plasma failure can be conceptualized as a state in which these mechanisms are overwhelmed and unable to constrain coagulation and inflammation appropriately. This dysregulated state causes widespread tissue damage and multiple organ dysfunction syndrome. Unlike plasma derangements caused by individual factors, plasma failure is characterized by a heterogeneous set of plasma component deficiencies and excesses. Targeted therapies such as factor replacement or recombinant antibodies are thus inadequate to restore plasma function. Therapeutic plasma exchange offers the unique ability to remove harmful factors and replete exhausted components, thereby reestablishing appropriate regulation of coagulation and inflammation.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22147Subventions
Organisme : NIH HHS
ID : R01GM108618
Pays : United States
Informations de copyright
© 2024 The Author(s). Journal of Clinical Apheresis published by Wiley Periodicals LLC.
Références
J. P. Wood, P. E. R. Ellery, S. A. Maroney, and A. E. Mast, “Biology of Tissue Factor Pathway Inhibitor,” Blood 123, no. 19 (2014): 2934–2943.
M. W. Radomski, R. M. J. Palmer, and S. Moncada, “Endogenous Nitric Oxide Inhibits Human Platelet Adhesion to Vascular Endothelium,” Lancet 330, no. 8567 (1987): 1057–1058.
F. A. Martin, R. P. Murphy, and P. M. Cummins, “Thrombomodulin and the Vascular Endothelium: Insights Into Functional, Regulatory, and Therapeutic Aspects,” American Journal of Physiology. Heart and Circulatory Physiology 304, no. 12 (2013): H1585–H1597.
S. M. Opal, C. M. Kessler, J. Roemisch, and S. Knaub, “Antithrombin, Heparin, and Heparan Sulfate,” Critical Care Medicine 30, no. 5 (2002): S325–S331.
H. H. Versteeg, J. W. Heemskerk, M. Levi, and P. H. Reitsma, “New Fundamentals in Hemostasis,” Physiological Reviews 93, no. 1 (2013): 327–358.
J. V. Sarma and P. A. Ward, “The Complement System,” Cell and Tissue Research 343, no. 1 (2011): 227–235.
F. Aktan, “iNOS‐Mediated Nitric Oxide Production and Its Regulation,” Life Sciences 75, no. 6 (2004): 639–653.
H. K. De Jong, T. Van Der Poll, and W. J. Wiersinga, “The Systemic Pro‐Inflammatory Response in Sepsis,” Journal of Innate Immunity 2, no. 5 (2010): 422–430.
K. Neubauer and B. Zieger, “Endothelial Cells and Coagulation,” Cell and Tissue Research 387, no. 3 (2022): 391–398.
J. Banchereau, V. Pascual, and A. O'Garra, “From IL‐2 to IL‐37: The Expanding Spectrum of Anti‐Inflammatory Cytokines,” Nature Immunology 13, no. 10 (2012): 925–931.
B. Shenkman and Y. Einav, “Thrombotic Thrombocytopenic Purpura and Other Thrombotic Microangiopathic Hemolytic Anemias: Diagnosis and Classification,” Autoimmunity Reviews 13, no. 4‐5 (2014): 584–586.
M. Schwameis, C. Schörgenhofer, A. Assinger, M. M. Steiner, and B. Jilma, “VWF Excess and ADAMTS13 Deficiency: A Unifying Pathomechanism Linking Inflammation to Thrombosis in DIC, Malaria, and TTP,” Thrombosis and Haemostasis 113, no. 4 (2015): 708–718.
D. M. Del Valle, S. Kim‐Schulze, H. H. Huang, et al., “An Inflammatory Cytokine Signature Predicts COVID‐19 Severity and Survival,” Nature Medicine 26, no. 10 (2020): 1636–1643.
Z. Varga, A. J. Flammer, P. Steiger, et al., “Endothelial Cell Infection and Endotheliitis in COVID‐19,” Lancet 395, no. 10234 (2020): 1417–1418.
A. Z. Zucoloto and C. N. Jenne, “Platelet‐Neutrophil Interplay: Insights Into Neutrophil Extracellular Trap (NET)‐Driven Coagulation in Infection,” Frontiers in Cardiovascular Medicine 20, no. 6 (2019): 85.
A. S. Kimball, A. T. Obi, J. A. Diaz, and P. K. Henke, “The Emerging Role of NETs in Venous Thrombosis and Immunothrombosis,” Frontiers in Immunology 27, no. 7 (2016): 236.
A. Bonaventura, A. Vecchié, L. Dagna, et al., “Endothelial Dysfunction and Immunothrombosis as Key Pathogenic Mechanisms in COVID‐19,” Nature Reviews. Immunology 21, no. 5 (2021): 319–329.
T. Iba, M. Levi, J. Thachil, and J. H. Levy, “Disseminated Intravascular Coagulation: The Past, Present, and Future Considerations,” Seminars in Thrombosis and Hemostasis 13, no. 48 (2022): 978–987.
N. M. Gourd and N. Nikitas, “Multiple Organ Dysfunction Syndrome,” Journal of Intensive Care Medicine 35, no. 12 (2020): 1564–1575.
J. C. Marshall, D. J. Cook, N. V. Christou, G. R. Bernard, C. L. Sprung, and W. J. Sibbald, “Multiple Organ Dysfunction Score: A Reliable Descriptor of a Complex Clinical Outcome,” Critical Care Medicine 23, no. 10 (1995): 1638–1652.
J. L. Vincent, A. De Mendonca, F. Cantraine, et al., “Use of the SOFA Score to Assess the Incidence of Organ Dysfunction/Failure in Intensive Care Units: Results of a Multicenter Prospective Study,” Critical Care Medicine 26, no. 11 (1998): 1793–1800.
S. P. Jackson, R. Darbousset, and S. M. Schoenwaelder, “Thromboinflammation: Challenges of Therapeutically Targeting Coagulation and Other Host Defense Mechanisms,” Blood 133, no. 9 (2019): 906–918.
K. Stellos, E. Maneta, E. Aivalioti, et al., “Endothelial Dysfunction and Immunothrombosis in Sepsis,” Frontiers in Immunology 4, no. 14 (2023): 1473.
J. L. Vincent and D. De Backer, “Microvascular Dysfunction as a Cause of Organ Dysfunction in Severe Sepsis,” Critical Care 9, no. 4 (2005): 1–4.
T. Watanabe, T. Imamura, K. Nakagaki, and K. Tanaka, “Disseminated Intravascular Coagulation in Autopsy Cases Its Incidence and Clinicopathologic Significance,” Pathology, Research and Practice 165, no. 4 (1979): 311–322.
T. Van Der Poll, J. D. de Boer, and M. Levi, “The Effect of Inflammation on Coagulation and Vice Versa,” Current Opinion in Infectious Diseases 24, no. 3 (2011): 273–278.
C. Fiuza, M. Bustin, S. Talwar, et al., “Inflammation‐Promoting Activity of HMGB1 on Human Microvascular Endothelial Cells,” Blood 101, no. 7 (2003): 2652–2660.
N. L. Denning, M. Aziz, S. D. Gurien, and P. Wang, “DAMPs and NETs in Sepsis,” Frontiers in Immunology 30, no. 10 (2019): 2536.
J. A. Kremer Hovinga and J. N. George, “Hereditary Thrombotic Thrombocytopenic Purpura,” New England Journal of Medicine 381, no. 17 (2019): 1653–1662.
J. N. George, “Corticosteroids and Rituximab as Adjunctive Treatments for Thrombotic Thrombocytopenic Purpura,” American Journal of Hematology 87, no. S1 (2012): S88–S91.
D. Annane, E. Bellissant, P. E. Bollaert, et al., “Corticosteroids for Treating Sepsis in Children and Adults,” Cochrane Database of Systematic Reviews 12 (2019): 1–162.
B. Rochwerg, S. J. Oczkowski, R. A. Siemieniuk, et al., “Corticosteroids in Sepsis: An Updated Systematic Review and Meta‐Analysis,” Critical Care Medicine 46, no. 9 (2018): 1411–1420.
J. L. Hsu and N. Safdar, “Polyclonal Immunoglobulins and Hyperimmune Globulins in Prevention and Management of Infectious Diseases,” Infectious Disease Clinics 25, no. 4 (2011): 773–788.
M. M. Alejandria, M. A. Lansang, L. F. Dans, and J. B. Mantaring, III, “Intravenous Immunoglobulin for Treating Sepsis, Severe Sepsis, and Septic Shock,” Cochrane Database of Systematic Reviews 9 (2013): 1–89.
U. Emmenegger, U. Frey, A. Reimers, et al., “Hyperferritinemia as Indicator for Intravenous Immunoglobulin Treatment in Reactive Macrophage Activation Syndromes,” American Journal of Hematology 68, no. 1 (2001): 4–10.
S. Grangé, G. Buchonnet, E. Besnier, et al., “The Use of Ferritin to Identify Critically Ill Patients With Secondary Hemophagocytic Lymphohistiocytosis,” Critical Care Medicine 44, no. 11 (2016): e1045–e1053.
L. Castillo and J. Carcillo, “Secondary Hemophagocytic Lymphohistiocytosis and Severe Sepsis/Systemic Inflammatory Response Syndrome/Multiorgan Dysfunction Syndrome/Macrophage Activation Syndrome Share Common Intermediate Phenotypes on a Spectrum of Inflammation,” Pediatric Critical Care Medicine 10, no. 3 (2009): 387–392.
D. Vela, Z. Vela‐Gaxha, M. Rexhepi, R. Olloni, V. Hyseni, and R. Nallbani, “Efficacy and Safety of Tocilizumab Versus Standard Care/Placebo in Patients With COVID‐19; a Systematic Review and Meta‐Analysis of Randomized Clinical Trials,” British Journal of Clinical Pharmacology 88, no. 5 (2022): 1955–1963.
RECOVERY Collaborative Group, “Tocilizumab in Patients Admitted to Hospital With COVID‐19 (RECOVERY): A Randomised, Controlled, Open‐Label, Platform Trial,” Lancet 397, no. 10285 (2021): 1637–1645.
REMAP‐CAP Investigators, “Interleukin‐6 Receptor Antagonists in Critically Ill Patients With Covid‐19,” New England Journal of Medicine 384, no. 16 (2021): 1491–1502.
C. J. Parker, S. Kar, and P. Kirkpatrick, “Eculizumab,” Nature Reviews. Drug Discovery 6, no. 7 (2007): 515–516.
C. M. Legendre, C. Licht, P. Muus, et al., “Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome,” New England Journal of Medicine 368, no. 23 (2013): 2169–2181.
E. Abraham, K. Reinhart, S. Opal, et al., “Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis: A Randomized Controlled Trial,” Journal of the American Medical Association 290, no. 2 (2003): 238–247.
M. Allingstrup, J. Wetterslev, F. B. Ravn, A. M. Møller, and A. Afshari, “Antithrombin III for Critically Ill Patients,” Cochrane Database of Systematic Reviews 2 (2016): 1–97.
V. M. Ranieri, B. T. Thompson, P. S. Barie, et al., “Drotrecogin Alfa (Activated) in Adults With Septic Shock,” New England Journal of Medicine 366, no. 22 (2012): 2055–2064.
J. Hogwood, E. Gray, and B. Mulloy, “Heparin, Heparan Sulphate and Sepsis: Potential New Options for Treatment,” Pharmaceuticals 16, no. 2 (2023): 271.
R. A. Brown, R. Lever, N. A. Jones, and C. P. Page, “Effects of Heparin and Related Molecules Upon Neutrophil Aggregation and Elastase Release In Vitro,” British Journal of Pharmacology 139, no. 4 (2003): 845–853.
N. Veraldi, A. J. Hughes, T. R. Rudd, et al., “Heparin Derivatives for the Targeting of Multiple Activities in the Inflammatory Response,” Carbohydrate Polymers 6, no. 117 (2015): 400–407.
R. Zarychanski, S. Doucette, D. Fergusson, et al., “Early Intravenous Unfractionated Heparin and Mortality in Septic Shock,” Critical Care Medicine 36, no. 11 (2008): 2973–2979.
F. Jaimes, G. De La Rosa, C. Morales, et al., “Unfractioned Heparin for Treatment of Sepsis: A Randomized Clinical Trial (The HETRASE Study),” Critical Care Medicine 37, no. 4 (2009): 1185–1196.
“Heparin Anticoagulation in Septic Shock (HALO),” ClinicalTrials.gov identifier NCT03378466, updated May 17, 2022, accessed February 22, 2023, https://www.clinicaltrials.gov/ct2/show/NCT03378466.
F. Dépret, A. Sitbon, S. Soussi, et al., “Intravenous Iloprost to Recruit the Microcirculation in Septic Shock Patients?,” Intensive Care Medicine 44 (2018): 121–122.
R. E. Berthelsen, S. R. Ostrowski, M. H. Bestle, and P. I. Johansson, “Co‐Administration of Iloprost and Eptifibatide in Septic Shock (CO‐ILEPSS)—A Randomised, Controlled, Double‐Blind Investigator‐Initiated Trial Investigating Safety and Efficacy,” Critical Care 23, no. 1 (2019): 1.
M. Legrand, H. A. Oufella, D. De Backer, et al., “The I‐MICRO Trial, Ilomedin for Treatment of Septic Shock With Persistent Microperfusion Defects: A Double‐Blind, Randomized Controlled Trial‐Study Protocol for a Randomized Controlled Trial,” Trials 21, no. 1 (2020): 1.
M. H. Bestle, N. E. Clausen, P. Soe‐Jensen, et al., “Efficacy and Safety of Iloprost in Patients With Septic Shock‐Induced Endotheliopathy—Protocol for the Multicenter Randomized, Placebo‐Controlled, Blinded, Investigator‐Initiated Trial,” Acta Anaesthesiologica Scandinavica 64, no. 5 (2020): 705–711.
B. Angekort, N. Maurin, and K. Boateng, “Influence of Pentoxifylline on Erythrocyte Deformability in Peripheral Occlusive Arterial Disease,” Current Medical Research and Opinion 6, no. 4 (1979): 255–258.
R. Coimbra, H. Melbostad, and D. B. Hoyt, “Effects of Phosphodiesterase Inhibition on the Inflammatory Response After Shock: Role of Pentoxifylline,” Journal of Trauma and Acute Care Surgery 56, no. 2 (2004): 442–449.
K. H. Staubach, J. Schroder, F. Stuber, K. Gehrke, E. Traumann, and P. Zabel, “Effect of Pentoxifylline in Severe Sepsis: Results of a Randomized, Double‐Blind, Placebo‐Controlled Study,” Archives of Surgery 133, no. 1 (1998): 94–100.
A. E. Shabaan, N. Nasef, B. Shouman, I. Nour, A. Mesbah, and H. Abdel‐Hady, “Pentoxifylline Therapy for Late‐Onset Sepsis in Preterm Infants: A Randomized Controlled Trial,” Pediatric Infectious Disease Journal 34, no. 6 (2015): e143–e148.
A. Hanlon and A. Metjian, “Caplacizumab in Adult Patients With Acquired Thrombotic Thrombocytopenic Purpura,” Therapeutic Advances in Hematology 11 (2020): 2040620720902904.
F. Peyvandi and C. Duby, “Caplacizumab, Anti‐Vwf Nanobody Potentially Changing the Treatment Paradigm in Thrombotic Thrombocytopenic Purpura: Results of the TITAN Trial,” Blood 124, no. 21 (2014): 229.
M. Scully, C. Sr, F. Peyvandi, et al., “Results of the Randomized, Double‐Nlind, Placebo‐Controlled, Phase 3 Hercules Study of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura,” Blood 130 (2017): LBA‐1.
L. M. Asmis, A. Serra, A. Krafft, et al., “Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura,” New England Journal of Medicine 387, no. 25 (2022): 2356–2361.
L. Connelly‐Smith, C. R. Alquist, N. A. Aqui, et al., “Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach From the Writing Committee of the American Society for Apheresis: The Ninth Special Issue,” Journal of Clinical Apheresis 38, no. 2 (2023): 77–278.
J. Lu, L. Zhang, C. Xia, and Y. Tao, “Complications of Therapeutic Plasma Exchange,” Medicine 98, no. 50 (2019): e18308.
G. Sik, A. Demirbuga, A. Annayev, A. Akcay, A. Çıtak, and G. Öztürk, “Therapeutic Plasma Exchange in Pediatric Intensive Care: Indications, Results, and Complications,” Therapeutic Apheresis and Dialysis 24, no. 2 (2020): 221–229.
M. François, D. Daubin, D. Menouche, et al., “Adverse Events and Infectious Complications in the Critically Ill Treated by Plasma Exchange: A Five‐Year Multicenter Cohort Study,” Critical Care Explorations 5, no. 11 (2023): e0988.
H. Knaup, K. Stahl, B. M. Schmidt, et al., “Early Therapeutic Plasma Exchange in Septic Shock: A Prospective Open‐Label Nonrandomized Pilot Study Focusing on Safety, Hemodynamics, Vascular Barrier Function, and Biologic Markers,” Critical Care 22 (2018): 1.
K. Stahl, J. J. Schmidt, B. Seeliger, et al., “Effect of Therapeutic Plasma Exchange on Endothelial Activation and Coagulation‐Related Parameters in Septic Shock,” Critical Care 24 (2020): 1–9.
R. Maiwall, M. Bajpai, A. Singh, et al., “Standard‐Volume Plasma Exchange Improves Outcomes in Patients With Acute Liver Failure: A Randomized Controlled Trial,” Clinical Gastroenterology and Hepatology 20, no. 4 (2022): e831–e854.
F. S. Larsen, L. E. Schmidt, C. Bernsmeier, et al., “High‐Volume Plasma Exchange in Patients With Acute Liver Failure: An Open Randomised Controlled Trial,” Journal of Hepatology 64, no. 1 (2016): 69–78.
B. Bjorvatn, L. Bjertnaes, H. O. Fadnes, et al., “Meningococcal Septicaemia Treated With Combined Plasmapheresis and Leucapheresis or With Blood Exchange,” British Medical Journal 288, no. 6415 (1984): 439–441.
N. E. Vain, J. R. Maziumian, W. Swarner, and C. C. Cha, “Role of Exchange Transfusion in the Treatment of Severe Septicemia,” Pediatrics 66, no. 5 (1980): 693–697.
J. Weng, M. Chen, D. Fang, D. Liu, R. Guo, and S. Yang, “Therapeutic Plasma Exchange Protects Patients With Sepsis‐Associated Disseminated Intravascular Coagulation by Improving Endothelial Function,” Clinical and Applied Thrombosis/Hemostasis 27 (2021): 10760296211053313.
R. Busund, V. Koukline, U. Utrobin, and E. Nedashkovsky, “Plasmapheresis in Severe Sepsis and Septic Shock: A Prospective, Randomised, Controlled Trial,” Intensive Care Medicine 28 (2002): 1434–1439.
K. Stahl, P. Wand, B. Seeliger, et al., “Clinical and Biochemical Endpoints and Predictors of Response to Plasma Exchange in Septic Shock: Results From a Randomized Controlled Trial,” Critical Care 26, no. 1 (2022): 134.
J. H. Reeves, W. W. Butt, F. Shann, et al., “Continuous Plasmafiltration in Sepsis Syndrome,” Critical Care Medicine 27, no. 10 (1999): 2096–2104.
X. Luo, X. Li, X. Lai, et al., “Chinese Critical Care Nutrition Trials Group. Therapeutic Plasma Exchange in Patients With Sepsis: Secondary Analysis of a Cluster‐Randomized Controlled Trial,” Journal of Clinical Apheresis 38, no. 1 (2023): 55–62.
E. J. Long, F. Shann, G. Pearson, D. Buckley, and W. Butt, “A Randomised Controlled Trial of Plasma Filtration in Severe Paediatric Sepsis,” Critical Care and Resuscitation 15, no. 3 (2013): 198–204.
T. C. Nguyen, Y. Y. Han, J. E. Kiss, et al., “Intensive Plasma Exchange Increases a Disintegrin and Metalloprotease With Thrombospondin Motifs‐13 Activity and Reverses Organ Dysfunction in Children With Thrombocytopenia‐Associated Multiple Organ Failure,” Critical Care Medicine 36, no. 10 (2008): 2878–2887.
D. Yan, R. Yao, X. Xie, et al., “The Therapeutic Efficacy of Plasmapheresis for Sepsis With Multiple Organ Failure: A Propensity Score‐Matched Analysis Based on the MIMIC‐IV Database,” Shock 61 (2023): 685–694, https://doi.org/10.1097/SHK.0000000000002254.
O. P. E. Lee, N. Kanesan, E. H. Leow, et al., “Survival Benefits of Therapeutic Plasma Exchange in Severe Sepsis and Septic Shock: A Systematic Review and Meta‐Analysis,” Journal of Intensive Care Medicine 38, no. 7 (2023): 598–611.
V. Kuklin, M. Sovershaev, J. Bjerner, et al., “Influence of Therapeutic Plasma Exchange Treatment on Short‐Term Mortality of Critically Ill Adult Patients With Sepsis‐Induced Organ Dysfunction: A Systematic Review and Meta‐Analysis,” Critical Care 28, no. 12 (2024): 12.
J. J. Chen, P. C. Lai, T. H. Lee, and Y. T. Huang, “Blood Purification for Adult Patients With Severe Infection or Sepsis/Septic Shock: A Network Meta‐Analysis of Randomized Controlled Trials,” Critical Care Medicine 51, no. 12 (2023): 1777–1789.
E. Rimmer, B. L. Houston, A. Kumar, et al., “The Efficacy and Safety of Plasma Exchange in Patients With Sepsis and Septic Shock: A Systematic Review and Meta‐Analysis,” Critical Care 18 (2014): 699.
J. D. Fortenberry, T. Nguyen, J. R. Grunwell, et al., “Therapeutic Plasma Exchange in Children With Thrombocytopenia‐Associated Multiple Organ Failure: The Thrombocytopenia‐Associated Multiple Organ Failure Network Prospective Experience,” Critical Care Medicine 47, no. 3 (2019): e173–e181.
B. Gucyetmez, H. K. Atalan, I. Sertdemir, U. Cakir, and L. Telci, “Therapeutic Plasma Exchange in Patients With COVID‐19 Pneumonia in Intensive Care Unit: A Retrospective Study,” Critical Care 24, no. 1 (2020): 492.
S. M. Kamran, Z. E. Mirza, A. Naseem, et al., “Therapeutic Plasma Exchange for Coronavirus Disease‐2019 Triggered Cytokine Release Syndrome; a Retrospective Propensity Matched Control Study,” PLoS One 16, no. 1 (2021): e0244853.
S. Al‐Hashami, F. Khamis, M. Al‐Yahyay, et al., “Therapeutic Plasma Exchange: A Potential Therapeutic Modality for Critically Ill Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection,” Journal of Clinical Apheresis 37, no. 6 (2022): 563–575.
F. Faqihi, A. Alharthy, S. Abdulaziz, et al., “Therapeutic Plasma Exchange in Patients With Life‐Threatening COVID‐19: A Randomised Controlled Clinical Trial,” International Journal of Antimicrobial Agents 57, no. 5 (2021): 106334.
E. E. Moore, H. B. Moore, L. Z. Kornblith, et al., “Trauma‐Induced Coagulopathy,” Nature Reviews. Disease Primers 8 (2021): 35.
S. A. Moore, M. A. Rollins‐Raval, J. M. Gillette, et al., “Therapeutic Plasma Exchange Is Feasible and Tolerable in Severely Injured Patients With Trauma‐Induced Coagulopathy,” Trauma Surgery & Acute Care Open 9, no. 1 (2024): e001126.
X. Li, C. Liu, Z. Mao, S. Qi, R. Song, and F. Zhou, “Effectiveness of Polymyxin B‐Immobilized Hemoperfusion Against Sepsis and Septic Shock: A Systematic Review and Meta‐Analysis,” Journal of Critical Care 63 (2021): 187–195.
D. Schädler, C. Pausch, D. Heise, et al., “The Effect of a Novel Extracorporeal Cytokine Hemoadsorption Device on IL‐6 Elimination in Septic Patients: A Randomized Controlled Trial,” PLoS One 12, no. 10 (2017): e0187015.
M. Heymann, R. Schorer, and A. Putzu, “Mortality and Adverse Events of Hemoadsorption With CytoSorb® in Critically Ill Patients: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials,” Acta Anaesthesiologica Scandinavica 66, no. 9 (2022): 1037–1050.
S. Zang, Q. Chen, Y. Zhang, L. Xu, and J. Chen, “Comparison of the Clinical Effectiveness of AN69‐oXiris Versus AN69‐ST Filter in Septic Patients: A Single‐Centre Study,” Blood Purification 51, no. 7 (2022): 617–629.
H. Stockmann, P. Thelen, F. Stroben, et al., “CytoSorb Rescue for COVID‐19 Patients With Vasoplegic Shock and Multiple Organ Failure: A Prospective, Open‐Label, Randomized Controlled Pilot Study,” Critical Care Medicine 50, no. 6 (2022): 964–976.